Escherichia Patents (Class 424/169.1)
  • Patent number: 9957316
    Abstract: Gastrokine-1 (Gkn-1) is a stomach protein that protects the gastrointestinal (GI) tract and has properties to manipulate smooth muscle contraction, prevent NSAID-induced ulceration of the gastrointestinal tract of a mammal, inhibit growth and survival of cancer cells and induce weight loss in a mammal. Previously this protein was designated AMP-18.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: May 1, 2018
    Assignee: LUMEN BIO LLC
    Inventor: David Lawrence Boone
  • Patent number: 9328150
    Abstract: The inventive subject matter relates to a recombinant polypeptide construct comprising enterotoxigenic Escherichia coli fimbrial subunits. The recombinant polypeptide constructs comprise multiple subunits to the same or different ETEC fimbrial types. The constructs are useful for inclusion in immunogenic formulations for the inductin of immunity against entertoxigenic Escherichia coli. The inventive subject matter also relates to the use of the recombinant polypeptide constructs in induce anti-enterotoxigenic Escherichia coli.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: May 3, 2016
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventor: Stephen Savarino
  • Patent number: 8926980
    Abstract: Anti-toxin compositions are described that include avian antibodies against bacterial toxins. Administration of the anti-toxin compositions binds and neutralizes the bacterial toxin in the animals. Methods of making the anti-toxin compositions against the bacterial toxins are also described. The anti-toxin compositions can be effective against pathogenic bacteria and also to decrease the amount of bacterial toxins in the individual, especially in the GI tract. The anti-toxin compositions can also act as anti-inflammatory agents.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: January 6, 2015
    Assignee: Camas Incorporated
    Inventors: Bradley M Mitteness, Connie Phillips
  • Publication number: 20140154265
    Abstract: The present invention relates to replication-competent Arteriviruses having a decreased DUB/deISGylating activity due to a mutation in the PLP2 domain of the non-structural protein nsp2, to their use as a medicament, their use as a vaccine and in prophylaxis, to vaccines comprising such Arteriviruses and to Arteriviral PLP2-ubiquitin complexes.
    Type: Application
    Filed: September 24, 2013
    Publication date: June 5, 2014
    Inventors: Marjolein Kikkert, Brian Leonard Mark, Puck Bertyne van Kasteren, Terrence William James, Eric John Snijder
  • Patent number: 8728478
    Abstract: The present invention relates to methods and compositions for the treatment and prevention of diarrhea and diarrheal related diseases and disorders in both animals and humans. In some embodiments, the invention relates to the treatment of said diarrhea and diarrheal related diseases and disorders with a vaccine. In still further embodiments, the invention relates to the treatment of constipation using the disclosed methods and compositions.
    Type: Grant
    Filed: September 3, 2009
    Date of Patent: May 20, 2014
    Assignee: Board of Trustees of Michigan State University
    Inventor: A. Mahdi Saeed
  • Publication number: 20140112938
    Abstract: The present invention provides a method of treatment or prophylaxis of enteric disease caused by Gram negative bacteria. The method includes the step of administering a vaccine or a hyperimmune material raised against said vaccine to an individual. The vaccine comprises one or more cell wall antigens reactive in a manner characteristic of O group serotypes, or reactive in a manner characteristic of lipopolysaccharide associated antigens, and at least some of said antigens are separated from bacterial cell walls or wall fragments. The invention also provides composition containing hyperimmune material as well as uses of the composition and vaccine.
    Type: Application
    Filed: December 23, 2013
    Publication date: April 24, 2014
    Applicant: Immuron Limited
    Inventors: Roy Michael Robins-Browne, Grant Thomas Rawlin, Gottfried Lichti
  • Publication number: 20140099328
    Abstract: Antibody product comprising n-specific antibodies characterized in that a) the n-specific antibodies in each case have an antibody content of at least 6/n % by weight of the total antibody component of the antibody product, and b) 2, 3 or more of the n-specific antibodies target lipopolysaccharide-expressing microorganisms, and c) the total amount of n-specific antibodies is 7% by weight of the total anti-body content of the antibody product.
    Type: Application
    Filed: March 28, 2012
    Publication date: April 10, 2014
    Applicant: MAT-MALTA ADVANCED TECHNOLOGIES LIMITED
    Inventor: Jan Wesjohann
  • Publication number: 20140017258
    Abstract: Anti-toxin compositions are described that include avian antibodies against bacterial toxins. Administration of the anti-toxin compositions binds and neutralizes the bacterial toxin in the animals. Methods of making the anti-toxin compositions against the bacterial toxins are also described. The anti-toxin compositions can be effective against pathogenic bacteria and also to decrease the amount of bacterial toxins in the individual, especially in the GI tract. The anti-toxin compositions can also act as anti-inflammatory agents.
    Type: Application
    Filed: July 11, 2012
    Publication date: January 16, 2014
    Applicant: Camas Incorporated
    Inventors: Bradley M Mitteness, Connie Phillips
  • Patent number: 8623372
    Abstract: The present invention relates to antibodies immunologically specific for an attaching and effacing Escherichia coli (AEEC) virulence-associated protein, products, compositions and methods and to their use thereof in the prevention of an AEEC infection in a mammal. The antibody of the invention is immunologically specific for an AEEC virulence-associated protein and is capable of preventing an in vivo AEEC intestinal infection when administered to a mammal. The antibody of the invention is preferably useful for preventing the development of A/E intestinal lesions associated with the AEEC. This is achieved by preferably using IgY antibodies immunologically specific for one or more AEEC virulence-associated proteins, such as Eae, Tir, EspA and Paa.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: January 7, 2014
    Assignee: Valorisation-Recherche, Societe En commandite
    Inventors: John M. Fairbrother, Josée Harel, Isabelle Batisson, Francis Girard, Marie-Pierre Guimond
  • Publication number: 20130084292
    Abstract: An antagonist of the interaction between the Gp96 receptor and E. coli AIEC strains, for the prevention or treatment of inflammatory bowel disease. The antagonist is for specifically blocking or reducing the interaction between Gp96 receptor and the outer membrane vesicles (OMVs), typically the outer protein membrane OmpA of E. coli AIEC strains. The inventions provides for pharmaceutical compositions containing such an antagonist, which may be an antibody against gp96 or OmpA, or a gp96 or OmpA polypeptide. It may be combined to an antagonist of the interaction between the CEACAM6 receptor and E. coli AIEC strains, such as an anti-CEACAM6 antibody, a CEACAM6 polypeptide, or a mannoside or particle having a mannose unit. The invention also relates to a method for the diagnosis of inflammatory bowel disease, or of the determination of a predisposition of a person to develop inflammatory bowel disease.
    Type: Application
    Filed: April 15, 2011
    Publication date: April 4, 2013
    Applicant: UNIVERSITE D'AUVERGNE CLERMONT I
    Inventors: Arlette Darfeuille-Michaud, Paul Hofman, Nathalie Rolhion
  • Patent number: 8323668
    Abstract: The present invention describes a novel mechanism of adhesion by flagellated Gram-negative bacteria such as enterotoxigenic Escherichia coli (ETEC), where the bacteria secretes a protein, EtpA which binds to the conserved region of the flagellin protein located at the tip of the flagella. The present invention also discloses that EtpA-mediated interaction and intestinal colonization require interaction with flagellin. Also disclosed herein is a vaccine composition that can be used for either active or passive immunization of mammals for the prevention or treatment of infections caused by flagellated Gram-negative bacteria.
    Type: Grant
    Filed: March 26, 2008
    Date of Patent: December 4, 2012
    Assignee: The University of Tennessee Research Foundation
    Inventor: James M. Fleckenstein
  • Publication number: 20120201834
    Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.
    Type: Application
    Filed: December 22, 2011
    Publication date: August 9, 2012
    Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
  • Publication number: 20120201833
    Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.
    Type: Application
    Filed: December 22, 2011
    Publication date: August 9, 2012
    Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
  • Publication number: 20120177650
    Abstract: A method and composition for treating enteric pathogen infections in animals suffering from such infections or displaying diseases or conditions consistent with such infections or for preventing or reducing the likelihood of enteric pathogen infections in animals at risk for developing such infections.
    Type: Application
    Filed: September 22, 2010
    Publication date: July 12, 2012
    Inventor: Thomas Julius Borody
  • Publication number: 20110300185
    Abstract: The present invention relates to methods and compositions for the treatment and prevention of diarrhea and diarrheal related diseases and disorders in both animals and humans. In some embodiments, the invention relates to the treatment of said diarrhea and diarrheal related diseases and disorders with a vaccine. In still further embodiments, the invention relates to the treatment of constipation using the disclosed methods and compositions.
    Type: Application
    Filed: September 3, 2009
    Publication date: December 8, 2011
    Inventor: Mahdi A. Saeed
  • Publication number: 20110236306
    Abstract: This invention provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system.
    Type: Application
    Filed: March 28, 2011
    Publication date: September 29, 2011
    Inventors: STEVEN D. GOODMAN, LAUREN O. BAKALETZ
  • Publication number: 20110206694
    Abstract: The present invention describes a novel mechanism of adhesion by flagellated Gram-negative bacteria such as enterotoxigenic Escherichia coli (ETEC), where the bacteria secretes a protein, EtpA which binds to the conserved region of the flagellin protein located at the tip of the flagella. The present invention also discloses that EtpA-mediated interaction and intestinal colonization require interaction with flagellin. Also disclosed herein is a vaccine composition that can be used for either active or passive immunization of mammals for the prevention or treatment of infections caused by flagellated Gram-negative bacteria.
    Type: Application
    Filed: March 26, 2008
    Publication date: August 25, 2011
    Inventor: James M. Fleckenstein
  • Publication number: 20110200616
    Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.
    Type: Application
    Filed: April 21, 2011
    Publication date: August 18, 2011
    Applicant: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub, Donavan E. Zammert, Gayla K. Kallevig
  • Patent number: 7910096
    Abstract: Human and humanized monoclonal antibodies which binds specifically to subunit A of Shiga like toxin II have been developed which are effective to prevent or ameliorate one or more symptoms of HUS in a human. Effective dosages for treatment or prevention range from approximately 0.1 to 5.0 mg of antibody/kg of patient weight. The examples demonstrate the preferred dosage ranges based on the pig model, and what is being tested in phase I clinical trials. Antibodies are preferably transfused over a period of two hours, although this will depend on the patient and the disease state at the time of treatment. Preferred dosages for treatment of humans are between 0.1 mg/kg-5.0 mg/kg of 5C120, or an equivalent dosage of another antibody to subunit A of STX2. In the most preferred embodiments, dosages of 0.1 mg/kg, 0.5 mg/kg, or 5.0 mg/kg of 5C12 (low dose, anticipated therapeutic dose based on animal data and high dose) are administered.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: March 22, 2011
    Assignee: Trustees of Tufts College
    Inventors: Saul Tzipori, Ramaswamy Balakrishnan, Arthur Donohue-Rolfe
  • Patent number: 7910095
    Abstract: Novel human monoclonal antibodies derived from a transgenic mouse are disclosed as well as a process for the preparation of the novel monoclonals and a therapeutic method of treating an individual for hemolytic uremic syndrome or of protecting an individual against hemolytic uremic syndrome by administration of the monoclonals to the individual in need of treatment or protection.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: March 22, 2011
    Assignee: Trustees of Tufts College
    Inventors: Saul Tzipori, Ramaswamy Balakrishnan, Arthur Donohue-Rolfe
  • Publication number: 20110059086
    Abstract: Disclosed are EspFU (EspF-like polypeptide encoded by a gene of the cryptic prophage CP-933U of enterohemorrhagic E. coli) polypeptides, fragments thereof, nucleic acids that encode EspFU polypeptides, or fragments thereof, and cells including the polypeptides, fragments, and/or nucleic acids. Also disclosed are model systems, kits, and methods for screening that use, for example, EspFU polypeptides and nucleic acids. Also included are pharmaceutical and diagnostic compositions and methods of diagnosis and treatment of EHEC infections.
    Type: Application
    Filed: June 7, 2010
    Publication date: March 10, 2011
    Applicant: UNIVERSITY OF MASSACHUSETTS
    Inventors: John M. Leong, Kenneth G. Campellone
  • Publication number: 20110020216
    Abstract: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated therein or thereon, or diffusing from the scaffold composition such that the scaffold composition and/or a bioactive composition captures and eliminates undesirable cells from the body a mammalian subject. The devices mediate active recruitment, sequestration, and removal or elimination of undesirable cells from their host.
    Type: Application
    Filed: June 11, 2008
    Publication date: January 27, 2011
    Inventors: David James Mooney, Omar abdel-Rahman Ali
  • Patent number: 7807134
    Abstract: Described is a multi drug multiligand conjugate for targeted drug delivery. The MDML conjugate contains a plurality of tripartite molecules linked to a central scaffold moiety, with each tripartite molecule comprising a targeting molecule, a therapeutic agent and a scaffold binding element. The MDML conjugate allows for more efficient delivery of therapeutic agents to the cells resulting in enhanced therapeutic efficiency. A model MDL conjugate is disclosed as well as method for the synthesis of the model conjugate.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: October 5, 2010
    Inventor: Ahmad Safavy
  • Patent number: 7794720
    Abstract: The present invention relates to isolated canine animal plasma, a method for isolating canine animal plasma, plasma obtained form an immunised or hyperimmunised canine animal and treating a canine animal with the isolated canine animal plasma. The method includes the step of selecting a canine animal having a blood group compatible with a recipient canine animal having an unmatched blood group, namely, selecting a canine animal for a blood group that does not cause plasma transfusion reaction and/or haemolysis. In one form, the method includes the step of immunising or hyperimmunising a canine animal plasma donor with one or more antigens of a canine animal pathogen. The pathogen is preferably a bacteria or virus.
    Type: Grant
    Filed: April 29, 2004
    Date of Patent: September 14, 2010
    Assignee: Plasma Ventures Pty Ltd
    Inventor: Ross Phillip Wilson
  • Publication number: 20100183627
    Abstract: The present invention relates to antibodies immunologically specific for an attaching and effacing Escherichia coli (AEEC) virulence-associated protein, products, compositions and methods and to their use thereof in the prevention of an AEEC infection in a mammal. The antibody of the invention is immunologically specific for an AEEC virulence-associated protein and is capable of preventing an in vivo AEEC intestinal infection when administered to a mammal. The antibody of the invention is preferably useful for preventing the development of A/E intestinal lesions associated with the AEEC. This is achieved by preferably using IgY antibodies immunologically specific for one or more AEEC virulence-associated proteins, such as Eae, Tir, EspA and Paa.
    Type: Application
    Filed: March 26, 2010
    Publication date: July 22, 2010
    Inventors: John M. Fairbrother, Josée Harel, Isabelle Batisson, Francis Girard, Marie-Pierre Guimond
  • Patent number: 7727531
    Abstract: The present invention relates to antibodies immunologically specific for an attaching and effacing Escherichia coli (AEEC) virulence-associated protein, products, compositions and methods and to their use thereof in the prevention of an AEEC infection in a mammal. The antibody of the invention is immunologically specific for an AEEC virulence-associated protein and is capable of preventing an in vivo AEEC intestinal infection when administered to a mammal. The antibody of the invention is preferably useful for preventing the development of A/E intestinal lesions associated with the AEEC. This is achieved by preferably using IgY antibodies immunologically specific for one or more AEEC virulence-associated proteins, such as Eae, Tir, EspA and Paa.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: June 1, 2010
    Assignee: Valorisation-Recherche, Societe En commandite
    Inventors: John M. Fairbrother, Josée Harel, Isabelle Batisson, Francis Girard, Marie-Pierre Guimond
  • Patent number: 7713527
    Abstract: Piglet feed is supplemented with anti-E. coli K88 antibody-containing egg powder having a titer of the K88 antibodies of at least 1/256,000 as a means of improving growth performance of piglets.
    Type: Grant
    Filed: September 18, 2006
    Date of Patent: May 11, 2010
    Inventors: Maiti Pradip, John Hare
  • Publication number: 20090220522
    Abstract: The present invention describes a detoxified Gram negative J5 core lipopolysaccharide/group B meningococcal outer membrane protein complex vaccine given in conjunction with CpG 7909 adjuvant. This vaccine composition can be used for either active or passive immunization of mammals for the prevention or treatment of sepsis and infection with Gram negative bacteria. The addition of CpG to the vaccine was shown to markedly increase the antibody response in mice. Furthermore, the ability of the endotoxin vaccine in protecting against Gram-negative bacteria such as Francisella tularensis in vivo is also demonstrated herein.
    Type: Application
    Filed: October 24, 2006
    Publication date: September 3, 2009
    Inventors: Alan S. Cross, Apurba K. Bhattacharjee, Wendell D. Zollinger, Steven M. Opal
  • Publication number: 20090214531
    Abstract: The invention features methods and compositions for treating or preventing Gram-negative bacterial infections.
    Type: Application
    Filed: January 29, 2007
    Publication date: August 27, 2009
    Inventors: John Mekalanos, Stefan Pukatzki, Joseph Mougous
  • Patent number: 7553490
    Abstract: This invention relates to conjugates of the O-specific polysaccharide of E. coli O157 with a carrier, and compositions thereof, and to methods of using of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in mammals, including responses which provide protection against, or reduce the severity of, bacterial infections. More particularly it relates to the use of polysaccharides containing the tetrasaccharide repeat unit: (?3)-?-DGalpNAc-(1?2)-?-D-PerpNAc-(1?3) -?-L-Fucp-(1?4)-?-D-Glcp-(1?), and conjugates thereof, to induce serum antibodies having bactericidal (killing) activity against hemolytic-uremic syndrome (HUS) causing E. coli, in particular E. coli O157. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies which have bactericidal or bacteriostatic activity against E. coli, in particular E. coli O157, and are useful to prevent and/or treat illnesses caused by E. coli O157.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: June 30, 2009
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Shousun Chen Szu, John B. Robbins, Yvonne Ageyman Konadu, legal representative, Edward Konadu
  • Publication number: 20090092621
    Abstract: The present invention relates to antibodies immunologically specific for an attaching and effacing Escherichia coli (AEEC) virulence-associated protein, products, compositions and methods and to their use thereof in the prevention of an AEEC infection in a mammal. The antibody of the invention is immunologically specific for an AEEC virulence-associated protein and is capable of preventing an in vivo AEEC intestinal infection when administered to a mammal. The antibody of the invention is preferably useful for preventing the development of A/E intestinal lesions associated with the AEEC. This is achieved by preferably using IgY antibodies immunologically specific for one or more AEEC virulence-associated proteins, such as Eae, Tir, EspA and Paa.
    Type: Application
    Filed: October 24, 2008
    Publication date: April 9, 2009
    Inventors: John M. Fairbrother, Josee Harel, Isabelle Batisson, Francis Girard, Marie-Pierre Guimond
  • Publication number: 20090081236
    Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.
    Type: Application
    Filed: April 11, 2008
    Publication date: March 26, 2009
    Applicant: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub
  • Patent number: 7445782
    Abstract: The present invention relates to antibodies immunologically specific for an attaching and effacing Escherichia coli (AEEC) virulence-associated protein, products, compositions and methods and to their use thereof in the prevention of an AEEC infection in a mammal. The antibody of the invention is immunologically specific for an AEEC virulence-associated protein and is capable of preventing an in vivo AEEC intestinal infection when administered to a mammal. The antibody of the invention is preferably useful for preventing the development of A/E intestinal lesions associated with the AEEC. This is achieved by preferably using IgY antibodies immunologically specific for one or more AEEC virulence-associated proteins, such as Eae, Tir, EspA and Paa.
    Type: Grant
    Filed: March 14, 2002
    Date of Patent: November 4, 2008
    Assignee: Valorisation-Recherche, Societe en Commandite
    Inventors: John M. Fairbrother, Josée Harel, Isabelle Batisson, Francis Girard, Marie-Pierre Guimond
  • Patent number: 7311892
    Abstract: Described is a multi drug multiligand conjugate for targeted drug delivery. The MDML conjugate contains a plurality of tripartite molecules linked to a central scaffold moiety, with each tripartite molecule comprising a targeting molecule, a therapeutic agent and a scaffold binding element. The MDML conjugate allows for more efficient delivery of therapeutic agents to the cells resulting in enhanced therapeutic efficiency. A model MDL conjugate is disclosed as well as method for the synthesis of the model conjugate.
    Type: Grant
    Filed: October 28, 2002
    Date of Patent: December 25, 2007
    Assignee: The UAB Research Foundation
    Inventor: Ahmad Safavy
  • Patent number: 7291334
    Abstract: Novel proteins and their corresponding nucleotide sequences in enteroaggregative Escherichia coli (EAEC) are provided. In particular, Aap and the five gene cluster (aat) of the AA probe region of the pAA plasmid of EAEC 042 have been identified, sequenced, and further characterized. The use of these novel proteins and their corresponding nucleotide sequences for diagnosis, therapy, and prevention of EAEC infections is also provided.
    Type: Grant
    Filed: April 14, 2006
    Date of Patent: November 6, 2007
    Assignee: University of Maryland, Baltimore
    Inventor: James Nataro
  • Patent number: 7285539
    Abstract: The invention provides a method of activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. HCV-specific T cells are activated using fusion proteins comprising HCV NS3, NS4, NS5a, and NS5b polypeptides, polynucleotides encoding such fusion proteins, or polypeptide or polynucleotide compositions containing the individual components of these fusions. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize a mammal against HCV.
    Type: Grant
    Filed: February 3, 2003
    Date of Patent: October 23, 2007
    Assignee: Chiron Corporation
    Inventors: Xavier Paliard, Michael Houghton, Mark Selby
  • Patent number: 7276240
    Abstract: Novel proteins and their corresponding nucleotide sequences in enteroaggregative Escherichia coli (EAEC) are provided. In particular, Aap and the five gene cluster (aat) of the AA probe region of the pAA plasmid of EAEC 042 have been identified, sequenced, and further characterized. The use of these novel proteins and their corresponding nucleotide sequences for diagnosis, therapy, and prevention of EAEC infections is also provided.
    Type: Grant
    Filed: April 14, 2006
    Date of Patent: October 2, 2007
    Assignee: University of Maryland, Baltimore
    Inventor: James Nataro
  • Patent number: 7238351
    Abstract: The method of producing a microbial adherence inhibitor for administration to food animals to control the incidents of acidosis in food animals by preventing the adherence of colony-forming lactic acid producing bacteria in the rumen or intestinal tracts of the food animals. The method includes inoculating female birds in or about their egg laying age with a lactic acid producing bacteria that colonizes in the intestinal tract of the food animal to be treated. Allowing a period of time sufficient to permit the production in the birds of antibody to the lactic acid producing bacteria and harvesting the eggs laid by such birds. The antibody-containing contents of the eggs are then separated by the shells.
    Type: Grant
    Filed: September 8, 2003
    Date of Patent: July 3, 2007
    Inventors: Peter Nash, Bradley M. Mitteness
  • Patent number: 7030101
    Abstract: Compositions and kits comprising combinations of ?-glucans and specific immunoglobulins are disclosed. The compositions and kits are useful in methods of preventing or treating infection by a pathogenic microorganism, in which ?-glucan is administered to a subject, and specific antibodies to a pathogenic microorganism are introduced into the subject.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: April 18, 2006
    Assignee: Nabi Biopharmaceuticals
    Inventors: Viliam Pavliak, Ali Ibrahim Fattom, Robert B. Naso
  • Patent number: 7025963
    Abstract: A vaccine, effective in inducing the production of antibodies with which to immunize a second subject passively against infection by Gram-negative bacteria and LPS-mediated pathology, comprises a non-covalent polyvalent complex formed between purified, detoxified LPS derived from E. coli and purified outer membrane protein derived from N. meningitidis. The same vaccine will also actively immunize a host subject against Gram-negative bacterial infections and LPS-mediated pathology. Meningococcal infections are included among those Gram-negative bacterial infections protected against by the vaccine.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: April 11, 2006
    Assignee: United States of America as represented by the Secretary of the Army
    Inventors: Apurba Bhattacharjee, Alan Cross, Jerald Sadoff, Wendell Zollinger
  • Patent number: 7018986
    Abstract: The invention provides methods of using beta glucans to treat conditions associated with bone loss or low bone density as well as methods for promoting bone growth in situations where enhanced bone growth is desirable. In the invention methods beta glucans are administered so as to enhance the development of osteoblasts and the inhibition of the development and recruitment of osteoclasts. The inhibition of the recruitment and development of osteoclasts, coupled with the enhancement of osteoblast maturation by beta glucans leads to decreased bone resorption and increased bone formation, making beta glucans ideal agents for the treatment of osteoporosis and other bone resorption diseases.
    Type: Grant
    Filed: February 12, 2003
    Date of Patent: March 28, 2006
    Assignee: Immudyne
    Inventors: Nino Sorgente, Harald L. Guenther, Hannelore E. Guenther, Arun K. Bahl
  • Patent number: 6942861
    Abstract: The present invention describes the isolation and purification of histidine-tagged functional portions of intimin (his-tagged intimin or his-intimin), a protein associated with the ability of certain strains of pathogenic bacteria to adhere to epithelial cells. The invention further describes the use of intimin as an antigen to promote a protective immune response. In addition, the invention describes the combination of intimin with one or more other antigens and administration of the combination to promote a protective immune response against intimin and the one or more antigens. One aspect of the invention is the administration of intimin to target specific epithelial cells to promote a protective immune response to intimin proteins. Additional aspects of the invention include the use of intimin or intimin combined with one or more antigens and administration of the combination to target gastrointestinal mucosa and stimulate an immune response.
    Type: Grant
    Filed: April 18, 1997
    Date of Patent: September 13, 2005
    Assignee: Henry M. Jackson Foundation for the Advancement of Military Medicine
    Inventors: Marian L. McKee, Alison D. O'Brien, Marian R. Wachtel
  • Patent number: 6790661
    Abstract: The invention provides methods for screening for the presence of a clinically relevant amount of bacteria in donor blood or a blood product from a donor mammal, particularly blood or a blood product that will be transferred from the donor mammal to a recipient mammal. The method comprises contacting a sample of the donor blood or a blood product with a set of binding agents that comprises binding agents that specifically bind to Gram-negative bacterial antigen and/or binding agents that specifically bind to Gram-positive bacterial antigen, and determining binding of the set of binding agents to the sample, wherein binding indicates the presence of a clinically relevant amount of Gram-positive bacteria and/or Gram-negative bacteria in the donor blood or blood product and no binding indicates the absence of a clinically relevant amount of Gram-positive bacteria and/or Gram-negative bacteria in the donor blood or blood product.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: September 14, 2004
    Assignee: Verax Biomedical, Inc.
    Inventor: Timothy T. Goodnow
  • Patent number: 6749831
    Abstract: Compare core LPS (lacking O-polysaccharide side chains) from Gram-negative bacteria are incorporated into a vaccine typically in liposomes. The complete core of E. coli K 12 is particularly useful. Upon administration to a mammal the vaccine stimulates synthesis of antibodies which are cross-protective against smooth and rough forms of LPS from at least two different Gram-negative bacterial strains having different core structures.
    Type: Grant
    Filed: April 25, 2000
    Date of Patent: June 15, 2004
    Assignee: Medical Defense Technology, LLC
    Inventors: Elliott Bennett-Guerrero, George Robin Barclay, Ian Raymond Poxton, Thomas James McIntosh, David Scott Snyder
  • Patent number: 6737063
    Abstract: The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. Also provided are methods for vaccination of mammalian species, especially human patients, with variants of the E. coli FimH protein, said variants being derived from different strains of E. coli, and to production of antibodies that protect the vaccine recipient against infection by pathogenic bacterial species. In another aspect the invention provides antibodies against such proteins and protein complexes that may be used as diagnostics and/or as protective/treatment agents for pathogenic bacterial species. A plasmid-based method of producing polypeptides, especially fused polypeptides, such as the complex of a bacterial chaperone and a bacterial adhesin, is also disclosed.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: May 18, 2004
    Assignee: MedImmune, Inc.
    Inventors: Solomon Langermann, Andrew Revel, Christine Auguste, Jeanne Burlein
  • Publication number: 20040086513
    Abstract: The present invention relates to antibodies immunologically specific for an attaching and effacing Escherichia coli (AEEC) virulence-associated protein, products, compositions and methods and to their use thereof in the prevention of an AEEC infection in a mammal. The antibody of the invention is immunologically specific for an AEEC virulence-associated protein and is capable of preventing an in vivo AEEC intestinal infection when administered to a mammal. The antibody of the invention is preferably useful for preventing the development of A/E intestinal lesions associated with the AEEC. This is achieved by preferably using IgY antibodies immunologically specific for one or more AEEC virulence-associated proteins, such as Eae, Tir, EspA and Paa.
    Type: Application
    Filed: November 12, 2003
    Publication date: May 6, 2004
    Inventors: John M. Fairbrother, Josee Harel, Isabelle Batisson, Francis Girard, Marie-Pierre Guimond
  • Patent number: 6713059
    Abstract: The present invention relates to an immunogenic conjugate comprising a carrier molecule coupled to an autoinducer of a Gram negative bacteria. The immunogenic conjugate, when combined with a pharmaceutically acceptable carrier, forms a suitable vaccine for mammals to prevent infection by the Gram negative bacteria. The immunogenic conjugate is also used to raise and subsequently isolate antibodies or binding portions thereof which are capable of recognizing and binding to the autoinducer. The antibodies or binding portions thereof are utilized in a method of treating infections, a method of inhibiting autoinducer activity, and in diagnostic assays which detect the presence of autoinducers or autoinducer antagonists in fluid or tissue samples.
    Type: Grant
    Filed: April 11, 2002
    Date of Patent: March 30, 2004
    Assignee: University of Rochester
    Inventors: Andrew S. Kende, Barbara H. Iglewski, Roger Smith, Richard P. Phipps, James P. Pearson
  • Patent number: 6652857
    Abstract: The present invention includes methods for generating neutralizing antitoxin directed against verotoxins. In preferred embodiments, the antitoxin directed against these toxins is produced in avian species using soluble recombinant verotoxin proteins. This antitoxin is designed so as to be administrable in therapeutic amounts and may be in any form (i.e., as a solid or in aqueous solution). These antitoxins are useful in the treatment of humans and other animals intoxicated with at least one bacterial toxin, as well as for preventive treatment, and diagnostic assays to detect the presence of toxin in a sample.
    Type: Grant
    Filed: June 16, 1999
    Date of Patent: November 25, 2003
    Assignee: Promega Corporation
    Inventors: James A. Williams, Lisa Marie Byrne, Charles S. G. Pugh
  • Patent number: 6605272
    Abstract: The present invention relates to zalpha11 Ligand polynucleotide and polypeptide molecules. The zalpha11 Ligand is a novel cytokine. The polypeptides may be used within methods for stimulating the proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: August 3, 2001
    Date of Patent: August 12, 2003
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • Publication number: 20030036639
    Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.
    Type: Application
    Filed: January 3, 2002
    Publication date: February 20, 2003
    Inventors: Daryll A. Emery, Darren E. Straub, Donavan E. Zammert, Gayla K. Kallevig